Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5919142 | 0.87 | — | — | |
| SCHEMBL27430861 | 0.83 | — | — | |
| SCHEMBL1513752 | 0.78 | — | — | |
| SCHEMBL120964 | 0.78 | — | — | |
| SCHEMBL2005416 | 0.77 | ELANE (0.32) | SPHK1 | |
| SCHEMBL5737479 | 0.76 | NPC1 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL20857076 | 0.76 | — | — | |
| SCHEMBL604277 | 0.74 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL24334485 | 0.73 | CHRM2 (0.37) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22856593 | 0.73 | SLC6A2 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12522571-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250281672-A1 | IDENTIFICATION OF PRO- AND ANTI-INFLAMMATORY LIPIDS RELATING TO IMMUNE RESPONSE TO MEDICAL IMPLANTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2024245193-A1 | HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2024-12-05 | — | — | WO | disclosed |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-11945786-B2 | Compounds, devices, and uses thereof | SIGILON THERAPEUTICS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2023010117-A1 | IDENTIFICATION OF PRO- AND ANTI-INFLAMMATORY LIPIDS RELATING TO IMMUNE RESPONSE TO MEDICAL IMPLANTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | CHRM2 964/4885CHRM4 1145/4885CHRM5 754/4885 |
| US-11945786-B2 | Compounds, devices, and uses thereof | SLC10A1, SLCO1B3, SLC5A1 | CHRM2 964/4885CHRM4 1145/4885CHRM5 754/4885 |
| US-20240279187-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | CHRM2 964/4885CHRM4 1145/4885CHRM5 754/4885 |
| US-20260109677-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | NR3C2, AGTR1, CHRM1 | CHRM2 20/4885CHRM4 178/4885CHRM5 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.